GeneDx Holdings (WGS) Depreciation & Amortization (CF) (2020 - 2022)

GeneDx Holdings (WGS) has reported Depreciation & Amortization (CF) for 5 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 24.54% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (up 24.54% YoY), while the FY2025 annual figure was $9.6 million, up 21.15% from the prior year.
• Depreciation & Amortization (CF) improved to $2.7 million in Q1 2026 per WGS's latest filing, from $2.2 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $5.8 million in Q1 2022 and bottomed at $2.2 million in Q1 2025.
• Historically, Depreciation & Amortization (CF) has averaged $3.6 million across 3 years, with a median of $2.7 million in 2026.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) gained 18.38% — and 2026, when it gained 24.54%.
• GeneDx Holdings' Depreciation & Amortization (CF) stood at $5.8 million in 2022, then plunged by 62.57% to $2.2 million in 2025, then increased by 24.54% to $2.7 million in 2026.
• Business Quant data shows WGS's Depreciation & Amortization (CF) at $2.7 million in Q1 2026, $2.2 million in Q1 2025, and $5.8 million in Q1 2022.